Digital Repository

Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?

Show simple item record

dc.contributor.author Carter, P.
dc.contributor.author Alifrangis, C.
dc.contributor.author Cereser, B.
dc.contributor.author Chandrasinghe, P.
dc.contributor.author Belluz, L.D.B.
dc.contributor.author Herzog, T.
dc.contributor.author Levitan, J.
dc.contributor.author Moderau, N.
dc.contributor.author Schwartzberg, L.
dc.contributor.author Tabassum, N.
dc.contributor.author Wen, J.
dc.contributor.author Krell, J.
dc.contributor.author Stebbing, J.
dc.date.accessioned 2018-03-07T09:30:10Z
dc.date.available 2018-03-07T09:30:10Z
dc.date.issued 2018
dc.identifier.citation Oncotarget.2018 en_US
dc.identifier.issn 1949-2553 (Electronic)
dc.identifier.issn 1949-2553 (Linking)
dc.identifier.uri http://repository.kln.ac.lk/handle/123456789/18622
dc.description.abstract We evaluated the effect of tailoring treatments based on predictions informed by tumor molecular profiles across a range of cancers, using data from Caris Life Sciences. These included breast carcinoma, colorectal adenocarcinoma, female genital tract malignancy, lung non-small cell lung cancer, neuroendocrine tumors, ovarian surface epithelial carcinomas, and urinary tract cancers.Molecular profiles using mostly immunohistochemistry (IHC) and DNA sequencing for tumors from 841 patients had been previously used to recommend treatments; some physicians followed the suggestions completely while some did not. This information was assessed to find out if the outcome was better for the patients where their received drugs matched recommendations.The IHC biomarker for the progesterone receptor and for the androgen receptor were found to be most prognostic for survival overall. The IHC biomarkers for P-glycoprotein (PGP), tyrosine-protein kinase Met (cMET) and the DNA excision repair protein ERCC1 were also shown to be significant predictors of outcome. Patients whose treatments matched those predicted to be of benefit survived for an average of 512 days, compared to 468 days for those that did not (P = 0.0684). In the matched treatment group, 34% of patients were deceased at the completion of monitoring, whereas this was 47% in the unmatched group (P = 0.0001). en_US
dc.language.iso en_US en_US
dc.publisher Impact Journals en_US
dc.subject molecular profiles en_US
dc.title Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients? en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


Browse

My Account